Pure Global AI
NCT06084936Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hoffmann-La RochePhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
Obinutuzumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hoffmann-La Roche
Location
Sioux Falls,Beijing,Changchun City,Chengdu City,Chongqing,Fuzhou City,Guangzhou,Nanning,Shanghai City,Wenzhou City,Bergamo,Alessandria,Torino,Daejeon,Seoul,Seoul,Seoul,Seoul,Cádiz,La Coruna,Barcelona,, China,Italy,South Korea,Spain,Taiwan,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Oct 22, 2023
End date
Dec 31, 2026
Enrollment
182 participants
Primary outcome

Progression-free survival (PFS)

Summary

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with
 an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with
 rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06084936
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06084936 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 182 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.